NRX Therapeutics

NRXP

Current ValuationThe current P/E ratio is -5.29, below the reasonable range, cheaper than 81.23% of the time in the past 1 years, and the industry ranks 165/255, the industry Median -1.31.

-5.29xP/E
Stock price$2.87Earnings per share$-0.54

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-53.89x148.12%$56.27B
BAYRYUSBayer
-24.13x--$48.69B
BAYZFUSBayer Aktiengesellschaft
-24.10x--$48.62B
VTRSUSViatris
-49.28x107.75%$20.24B
ELANUSElanco Animal Health
-56.52x129.36%$11.25B
AXSMUSAxsome Therap
-48.40x26.61%$9.28B
VREOFUSVIREO GROWTH INC
-132.19x--$8.87B
CURLFUSCuraleaf Holdings, Inc.
-143.59x--$7.47B
BLTEUSBelite Bio
-62.62x29.87%$6.41B
MANEUSVeraDermics
-47.62x97.44%$4.97B
DFTXUSDefinium Therapeutics
-13.76x53.61%$4.87B
EWTXUSEdgewise Therapeutics
-22.19x137.29%$4.38B
RGCUSRegencell Bioscience
-508.93x--$3.59B
AMLXUSAmylyx Pharmaceuticals
-22.93x1.76%$3.49B
ELVNUSEnliven Therapeutics
-31.45x6.39%$3.33B
TARSUSTarsus Pharmaceuticals
-70.30x205.82%$3.27B
MBXUSMBX Biosciences
-27.03x31.12%$2.82B
SUPNUSSupernus Pharma
-22.62x70.59%$2.49B
BHCUSBausch Health
-2.01x307.94%$2.20B
PHVSUSPharvaris BV
-10.79x9.52%$2.14B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.